Jasmine Kway - 03 Nov 2021 Form 4 Insider Report for VOLITIONRX LTD (VNRX)

Role: CEO - Singapore Volition
Signature: /s/ Jasmine Kway
Issuer symbol: VNRX
Transactions as of: 03 Nov 2021
Net transactions value: $0
Form type: 4
Filing time: 05 Nov 2021, 16:06:23 UTC
Next filing: 10 Dec 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VNRX	Stock Option (Right to Buy)	Disposed to Issuer	-50,000	-100%	0	03 Nov 2021	Common Stock	50,000	$4.80	Direct	F1
transaction	VNRX	Stock Option (Right to Buy)	Award	+50,000		50,000	03 Nov 2021	Common Stock	50,000	$4.80	Direct	F1
transaction	VNRX	Stock Option (Right to Buy)	Disposed to Issuer	-50,000	-100%	0	03 Nov 2021	Common Stock	50,000	$4.00	Direct	F2
transaction	VNRX	Stock Option (Right to Buy)	Award	+50,000		50,000	03 Nov 2021	Common Stock	50,000	$4.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 1, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 1, 2027 (ten years from the original date of grant).
F2	The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

Content

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 1, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 1, 2027 (ten years from the original date of grant).

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).